Because BNL tumor does not express MHC-II, the authors suggested that tumor killing in vitro likely occurred through the presentation of tumor antigens to DC/BNL-primed CD4+ CTLs leading to perforin-mediated MHC-independent killing of nearby MHC-II-negative tumor cells (37). The gene discussed is PRF1; the disease is neoplasm.